Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03038308 · OUTCOME

Number of Subjects With Stable or Decreased Tumor Size

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole · Source last updated 2024-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
6 months

What was measured

Number of subjects with stable or decreased tumor size from baseline assessment to assessment after 6 months of treatment. Radiologic assessment of tumor size before and after treatment will be made by MRI.

Analysis population: Nine participants analyzed as only 9 participants had a followup MRI at 6 months.

Groups in this outcome

ROP Intervention

Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ROP Intervention9

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ROP Intervention7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Number of subjects with stable or decreased tumor size from baseline assessment to assessment after 6 months of treatment. Radiologic assessment of tumor size before and after treatment will be made by MRI.
groups
  1. description
    Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
    id
    OG000
    title
    ROP Intervention
param Type
NUMBER
population Description
Nine participants analyzed as only 9 participants had a followup MRI at 6 months.
reporting Status
POSTED
time Frame
6 months
title
Number of Subjects With Stable or Decreased Tumor Size
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice